World Health Organization

FIFTH MEETING OF THE MEMBER STATE MECHANISM ON SUBSTANDARD/SPURIOUS/FALSELY-LABELLED FALSIFIED/COUNTERFEIT MEDICAL PRODUCTS
Geneva, 23–25 November 2016

A/MSM/5/1
4 November 2016

Provisional agenda

1. Opening of the meeting

2. Adoption of the agenda and method of work

3. Update on activities to implement the workplan

4. Update on implementation of the workplan and agreed list of prioritized activities for 2016–2017

(A) Develop recommendations for the health authorities engaged in the detection of substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) medical products and establish a strengthening and tool-generating programme to contribute to Member States' training

(B) Create a focal point network for the exchange of information and consultation at large among Member States and establish an ongoing virtual exchange forum

(C) Establish a working group to survey the technologies, methodologies and "track and trace" models in place and to be developed to analyse their advantages and disadvantages and to survey the available authentication and detection technologies and methodologies and analyse their advantages and disadvantages

(D) Identify WHO areas working on the issue of access to quality, safe, efficacious and affordable medical products and request a report on the current state of affairs

(E) Create a working group to develop and leverage existing recommendations for effective risk communication and recommendations for awareness campaigns on substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) medical products and related actions, activities and behaviours

(F) A proposal for a study on the public health and socioeconomic impact of substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) medical products

(G) Governance, management and secretariat costs to support the above activities[1]

[1] At its meeting on 28 and 29 September 2016, the Steering Committee of the Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) medical products recommended that item H be considered before item G.

(H) Modalities and budget implications of a Member State Mechanism working group of experts on refining the SSFFC working definitions, and an update on existing working definitions[1]

5. WHO's participation in the Global Steering Committee for Quality Assurance of Health Products

6. Update on WHO's activities for regulatory systems strengthening, and on the application of WHO's global benchmarking tool

7. Review of the Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products

8. Date of the next meeting

9. Report of the Member State mechanism to the Seventieth World Health Assembly, through the Executive Board at its 140th session

10. Closure of the meeting

= = =

[1] At its meeting on 28 and 29 September 2016, the Steering Committee of the Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC) medical products recommended that item H be considered before item G.